drug
nifurtimox
Marketedupdated 5mo agoby Bayer HealthCare Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying nifurtimox
- —An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
- phase3A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
- phase2Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 6, 2027
305 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
FDA exclusivities (2)
- Aug 6, 2027ODE-319Orphan Drug (7y)305d
- Aug 6, 2027ODE-319Orphan Drug (7y)305d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that